Authorization

Innovus Pharmaceuticals Announces $3.17 Million Private Placement

Innovus Pharmaceuticals, Inc. (OTCQB: INNV) ("Innovus Pharmaa?? or the
"Companya??), an emerging commercial-stage pharmaceutical company that
delivers safe, innovative and effective over-the-counter medicine and
consumer care products to improve mena??s and women's health and
respiratory diseases, today announced that it has entered into a
definitive agreement with a healthcare-dedicated institutional investor
for the sale of 45,306,347 shares of common stock (or common stock
equivalents), series A warrants to purchase up to 45,306,347 shares of
common stock and series B warrants to purchase up to 45,306,347 shares
of common stock in a private placement at a price of $0.07 per share and
associated warrants for gross proceeds of approximately $3.17 million.
The transaction is anticipated to close on or aboutA January 3, 2019,
subject to customary closing conditions.


H.C. Wainwright & Co. is acting as the exclusive placement agent for the
offering.


The series A warrants are exercisable immediately with a term of 18
months following the effectuation of a reverse stock split by the
Company and an exercise price of $0.07 and the series B warrants are
exercisable immediately with a term of 5A 1/2 years following the
effectuation of a reverse stock split by the Company and an exercise
price of $0.08 per share.


The net proceeds from the offering are anticipated to be approximately
$2.765 million. The Company intends to use the net proceeds for working
capital and general corporate purposes. The Company has agreed to file a
resale registration statement for the shares of common stock and the
shares of common stock underlying the warrants issued in the offering
within 30 days pursuant to a registration rights agreement.


The securities sold in the private placement have not been registered
under the Securities Act of 1933, as amended, or state securities laws
and may not be offered or sold in the United States absent registration
with the Securities and Exchange Commission (SEC) or an applicable
exemption from such registration requirements.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2019    »
ПнВтСрЧтПтСбВс
 1234
567891011
12131415161718
19202122232425
262728293031